Navigation Links
Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors
Date:8/29/2014

BOSTON, Aug. 29, 2014 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostics medical device company based in Boston announced today that T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd  was appointed to the company's Board of Directors.

"Teo Forcht Dagi is an experienced leader with a distinguished career in neurosurgery, medical innovation and venture capital," said Remis Bistras, President and CEO of Vittamed. "We are extremely delighted to add his clinical, strategic, and entrepreneurial expertise to our Board."

Dr. Dagi is a board certified neurosurgeon trained at the Massachusetts General Hospital. He holds faculty appointments at Harvard Medical School and Queen's University Belfast. He served as President of the Georgia Neurosurgical Society and as a Director of the American Association of Neurological Surgeons.  He has sat on numerous public and private boards, has been involved in many start-ups and early stage companies, and served as a partner at and advisor to prominent venture capital funds.  

"I am honored to join Vittamed at this exciting time in its history," said Dr. Dagi.  "With the recent CE mark approval for both its products and multiple near-term commercial opportunities, I look forward to helping Vittamed achieve its mission of delivering non-invasive neuromonitoring and diagnostics to patients with unmet medical needs."

He received an AB from Columbia, and an MD and MPH from Johns Hopkins. He holds an MBA with distinction from Wharton and was awarded a DMedSc (Honoris Causae) from Queen's University Belfast for contributions to medicine and public service. 

About Vittamed
Vittamed is a Boston-based company with R&D operations in Lithuania. Using ultrasound based technology, it has developed a suite of clinically proven and validated devices.  The Vittamed 205 is a non-invasive Intracranial Pressure (ICP) meter and the Vittamed 505 is a non-invasive Cerebrovascular Perfusion and Autoregulation monitoring device.  Multiple prospective clinical trials with several hundred patients have proven that the Vittamed devices deliver reliable, clinically acceptable, accurate and precise results as compared to today's standard of care using invasive intraventricular and lumbar puncture ICP measurements.  Recently Vittamed received CE mark for its both devices and is preparing for commercialization in the EU as well as 510 (k) filing in the US.

For more information, please visit www.vittamed.com


'/>"/>
SOURCE Vittamed Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
2. Meditope Biosciences Appoints Prominent Scientific Advisory Board
3. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
4. Sanomedics Signs Definitive Agreement for Acquisition of a prominent Texas based Sleep Services company.
5. Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
6. Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
7. La Jolla Neurosurgeon Introduces Cutting-Edge Surgery for Scoliosis Patients
8. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
9. Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures
10. Vivex Biomedical and Akron Biotech: Collaborative Venture in Regenerative Medicine
11. Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... DENVER , March 23, 2017  Drug ... pain medication misuse and deadly overdoses. A new ... Health Solutions, www.cordantsolutions.com , reports more detailed ... tests, which can potentially improve therapy adherence, patient ... The Cordant Comprehensive Oral fluid Rx Evaluation ...
(Date:3/23/2017)... , March 23, 2017  A new genetic ... accurate identification of individuals who carry HLA-B*15:02 ... a rare yet potentially deadly side effect of ... disorder.  The gene HLA-B*15:02 is strongly ... as Stevens-Johnson syndrome and toxic epidermal necrolysis in ...
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... devices market exhibits a consolidated vendor landscape with the ... the overall market in 2015. These companies are ... Industries, Inc., Hygia Health Services, Inc., and VANGUARD ... global reprocessed medical devices market is witnessing the ...
Breaking Medicine Technology:
(Date:3/23/2017)... Virginia (PRWEB) , ... March 23, 2017 , ... ... public health services to their communities, 16 more public health departments have been ... week’s decisions bring another 4.5 million people into the expanding network of communities ...
(Date:3/23/2017)... , ... March 23, 2017 , ... 82% of adults are unaware of the dangers ... not brush their teeth the minimum two times a day that dentists recommend. The ramifications ... 51 million hours of school and adults missing 164 million hours of work each year ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... investment in Los Angeles based healthcare technology company California Healthcom Group (CHG). ... the US, and healthcare arena. With headquarters in California, CHG is a growing, ...
(Date:3/23/2017)... ... ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 backers ... crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, LLC, ... excited to be operating on U.S. shores, where most of our initial crowdfunding backers ...
(Date:3/23/2017)... ... ... According to the National Sleep Foundation , poor sleep quality affects ... of the sunken-eye look, which can include dark circles or bags under the eyes. ... likely due to genetics, dehydration, allergies, and losing fat beneath the thin skin under ...
Breaking Medicine News(10 mins):